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Background: Sarcoidosis (SA) is a multisystem granulomatous disorder of unknown
etiology. It seems likely that in genetically different predisposed hosts, the same
antigen(s) may cause the development of sarcoid Th1 response. The interaction of the T-
cell receptor with the human leukocyte antigen-DQA1*03011 peptide-complex can affect T
lymphocytes activation in a dose-response manner.
Objectives/Methods: To test occurrence of DQA1*03011 allele in SA, we compared the
distribution of DQA1 alleles in 32 SA patients, 37 TB patients and in 58 healthy volunteers,
using a PCR-SSP ‘‘high-resolution’’ method.
Results: Our results revealed that after Bonferroni correction DQA1*03011 were less
common in SA patients than in the controls (OR 0.16, 95%CI 0.03–0.75). In TB, DQA1*0303
were significantly more frequent and DQA1*0505 less present as compared to the controls
(OR 11.03, 95% CI 1.20–95.80, OR 0.29, 95% CI 0.01–0.88). Comparing DQA1 alleles in both
patient groups, DQA1*0501, DQA1*0505 alleles were more common and DQA1*03011,
DQA1*0302, DQA1*0303 were less common after Bonferroni correction in SA than in TB.
Conclusion: We revealed that DQA1*03011 allele was less common in SA than in the
controls and TB. It seems possible that a low frequency of DQA1*03011 occurrence may be
also involved in the etiopathogenesis of SA.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Sarcoidosis (SA) is a multisystem granulomatous disorder of
unknown etiology. Infectious organisms, e.g. Mycobacteruim
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potential causes. The observations of the familial occur-
rence of SA or tuberculosis (TB) and the description of the
diseases in monozygotic twins, suggest the possibility the
genetic elements contribute to determining the course of
these diseases (reviewed in Refs. 1, 2).
It has been postulated that in the genetically predisposed
hosts, exposure to the persistent (auto)antigen, e.g.
mycobacterial heat shock proteins (hsp), triggers an
increased local cellular immune response, mediated by an
excess of CD4+T lymphocyte activity with a relative
decrease in CD8+T-cells, leading to sarcoid granuloma
formation.1 Particular epitopes of mycobacterial peptides
of hsp70, hsp65 and hsp16 binding selectively to the human
leukocyte antigen (HLA)-DR1/DR2/DR3/DR4/DR7/DRw53,
DQB1*0302 and DQA1*0301, affect the regulation of im-
munoreactivity of an organism to M. tuberculosis infection.2
Since the HLA-DR and -DQB antigens play an important
role in the regulation of the immune response, a possible
association between DQA1 alleles and SA has been examined
in Indian, Irish, Japanese and Swedish ethnic groups, but the
results have been controversial.3–6
Recently, few studies7–11 revealed that DQA1 alleles,
particularly DQA1*03011 may modulate the T-cell response
by disruption of the T cell receptor (TCR)-HLA-peptide
interaction through binding to HLA class II, cell-cycle arrest,
apoptosis, and deletion.Table 1 Distribution of DQA1 alleles in patients with sarcoidosis
(C).
HLA-DQA1
alleles
No. (counts) of antigen carriers in tested g
Controls
N ¼ 58 (%)
Sarcoidosis
N ¼ 32 (%)
DQA1*0101 11 (20) 6 (19)
DQA1*0102 23 (40) 15 (47)
DQA1*0103 8 (14) 7 (22)
DQA1*0104 1 (2) 0 (0)
DQA1*0201 15 (26) 8 (25)
DQA1*03011 17 (29) 2 (6)a
DQA1*0302 1 (2) 0 (0)
DQA1*0303 1 (2) 0 (0)
DQA1*0401 2 (3) 0 (0)
DQA1*0501 14 (24) 11 (34)
DQA1*0503 0 (0) 0 (0)
DQA1*0505 20 (34) 10 (31)
Data were analyzed using the computer program STATISTICA for Win
Bonferroni correction for repeated measurements at pp0.05; p-valu
was considered alone; a–cpc for comparison tested groups of patient
apco0.0001,
bpc ¼ 0.006,
cpc ¼ 0.01,
#pc for comparison SA vs. TB,
#pc ¼ 0.01,
ypc ¼ 0.04,
zpc ¼ 0.004,
pc ¼ 0.03,pco0.0001.Therefore, to test the frequency of occurrence of
DQA1*03011 allele in SA, we evaluated the distribution of
DQA1 alleles SA patients, TB patients and in healthy
volunteers in the same ethnic group in Poland (Table 1).Methods
Study subjects
Thirty-two unrelated patients with a newly detected
pulmonary SA (13 women and 19 men, mean age 37.5 years;
range 23–60 years) of the Pulmonology Hospital in Wejher-
owo, Poland, were included in the study. The SA diagnosis
was based on histological (scalenobiopsy of the lymph
nodes), clinical and radiological evidence. High Resolution
Computed Tomography was used to diagnose Stage I
(bilateral hilar lymphadenopathy—15 patients) and Stage
II (bilateral hilar lymphadenopathy and parenchymal infil-
trations—17 patients) of SA. None of the patients had
neither Lo¨fgren’s Syndrome nor extrapulmonary SA. Micro-
biological and cytological examination of the lymph nodes
and sputum samples revealed no acid-fast bacilli (PCR,
culture of the M. tuberculosis strain), fungi or atypical cells.
Disease outcome was evaluated in 32 of the patients,
categorizing them into resolving or nonresolving patients
depending on radiological signs of disease during 1.5 year(SA), patients with tuberculosis (TB) and in the control group
roups OR (95% CI)
Tuberculosis
N ¼ 37(%)
C vs. SA C vs. TB
9 (24)
15 (41)
8 (22)
3 (8)
5 (14)
9 (24)# 0.16
(0.03–0.75)
3 (8)y
6 (16)b,z 11.03 (1.20–95.80)
0 (0)
5 (14)
1 (3)
5 (14)c 0.29 (0.01–0.88)
dows, v. 7.1 (StatSoft, USA), using the chi-square test with the
es were corrected (pc) for the number of alleles when one locus
s vs. controls (C):
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(6%) patients with Stage II SA in the entire patient group had
a resolving disease.
Thirty-seven unrelated patients with a newly detected
active pulmonary TB (14 women and 23 men, mean age 40
years; range 22–68 years) of the Pulmonology Hospital in
Wejherowo, Poland, were included in the study. The
diagnosis of TB was established using standard clinical,
radiographic and bacteriological criteria (demonstration of
acid-fast bacilli in sputum smears and by positive sputum
culture of M. tuberculosis).
The control sample studied consisted of 58 unrelated
healthy blood donor (26 women and 32 men, mean age 42
years; range 27–60 years). All of them underwent routine
physical examination. They showed normal results of CXRs
and blood and serum tests and no acid-fast bacilli in sputum
smears and in the sputum culture of the M. tuberculosis
strain. None of the controls, SA or TB patients (non-smokers
as well as smokers) had a familial history of SA or TB. Testing
for HIV infection was performed in all groups. Polish
population is a relatively homogenous Caucasian ethnic
group. Ethical approval for the study was obtained from the
Independent Bioethics Committee for Scientific Researches,
Medical University of Gdan´sk, Poland. The informed consent
was obtained from both patients and controls.
Genotyping
DQA1 typing was performed using a sequence-specific
amplification (Polymerase Chain Reaction with Sequence
Specific Primers-PCR-SSP) following the method of Olerup et
al. (published previously in Ref. 2). Twelve alleles for DQA1
in PCR-SSP ‘‘high-resolution’’ were typed. The DQA1 primers
were supplied by DYNALs in standard DQA1-SSP kits.
Statistical analysis
The significance of differences in allele frequencies
between populations was evaluated using the chi-square
test after Bonferroni correction at pp0.05 and a multiple
polynomial logistic regression model was performed to
determine odds ratios (OR) with 95% confidence intervals
(CI) (STATISTICAs for Windows v. 7.1 software; StatSoft,
USA). p-Values were corrected (pc) for the number of alleles
when one locus was considered alone.
Results
Our results revealed a lower occurrence of DQA1*03011 allele
in the patients with SA than in the controls (pco0.0001). We
have found that DQA1*0303 allele was more common
(p ¼ 0.0005, pc ¼ 0.006) and DQA1*0201, DQA1*0505 alleles
were less common (p ¼ 0.03, pc40.05; p ¼ 0.0009,
pc ¼ 0.01 respectively) in TB than in the controls. When we
compared DQA1 alleles occurrence in both patient groups,
our results showed that DQA1*0201, DQA1*0501, DQA1*0505
alleles were more frequent in SA than in TB patients
(p ¼ 0.04, pc40.05; p ¼ 0.0009, pc ¼ 0.01; p ¼ 0.004,
pc ¼ 0.04, respectively). DQA1*03011, DQA1*0302 and
DQA1*0303 alleles were significantly rarer in patients withSA than in those with TB (p ¼ 0.0004, pc ¼ 0.004; p ¼ 0.003,
pc ¼ 0.03; po0.0001, pco0.0001, respectively).Discussion
Results of a few studies on the analysis of DQA1 alleles
polymorphisms in ethnically different groups of patients
with SA or TB are inconsistent (reviewed in Refs. 2, 7–10).
The data obtained for Indians with SA revealed significantly
more frequent occurrence of DQA1*0101, DQA1*0104,
whereas in Irish, Japanese, Swedish populations a significant
positive association was found between the occurrence of
DQA1*0501 allele and SA.3–6 Low risk of development of SA
associated with DQA1*0301/0302 was described in study
conducted by Berlin et al.,4 but DQA1*0301/0302 alleles
were not separated. In our patients with SA, DQA1*03011
allele was significantly less common as compared to healthy
people and TB patients. However, we were not able to
confirm a positive association with DQA1*0101 and
DQA1*0103 alleles as has been reported in Asian and Mexican
populations with TB (reviewed in Ref. 2). Other studies
(reviewed in Ref. 2) showed no significant correlation
between TB with DQ phenotypes in ethnically different
groups.
It has been recognized that HLA class II molecules are
present in both membrane-bound and soluble forms can
mediate immunoregulatory functions in vivo.11 More re-
cently, authors (reviewed in Ref. 8) demonstrated that
peptides derived from HLA molecules modulate immune
response both in vitro and in vivo. A synthetic peptide
corresponding to residues 75–84 of HLA-B2702 induces
T-cell anergy, probably by interaction with members of
hsp70.12 Other synthetic peptide corresponding to residues
65–79 of the a-chain of HLA-DQA1*03011 (DQ65–79) is
substantially anti-proliferative, blocking cell cycle progres-
sion at the early G1 to G1 restriction point transition
via interaction with proliferating cell nuclear antigen
(PCNA) and act downstream of the IL-2 receptor by
inhibiting PI 3-kinase and cyclin-dependent kinase 2 activ-
ity.8,9 DQ65–79, a peptide derived from residues 65–79 of
the a-chain of HLA-DQA1*03011, similarly to p21 (a key
regulator of cell growth and differentiation) induce
T-cell apoptosis and competitively inhibits binding of
p21 to PCNA.10 Murphy et al.13 revealed that the low
dose of human DQA1*03011 peptide stimulated IL-2 and
INF-g production and increased proliferation of CD4+T
lymphocytes.
It seems possible that a lower frequency of DQA1*03011
detected among our SA in comparison with the controls and
TB patients may be involved in the development of sarcoid
Th1 response, not in the protection against SA. Therefore,
we began to test an association a low presence of
DQA1*03011 with increased susceptibility to SA.Conflict of interest statement
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